INTRODUCTION

36
A current hot-spot of clinical research in 
147
The aMCI patients were classified into two 148 groups named "positive" (i.e., prodromal AD) and 149 "negative" (i.e., stable aMCI) based on baseline respectively. The assays dynamic ranges were 187 7.8-1000 pg/mL and 6.8-1000 pg/mL, respectively. deviations of the absorbance of blank, was 0.5 ng/ml.
195
The assay dynamic range was from 5 to 160 ng/mL. [22], the aMCI patients were classified as "positive" 254 (prodromal AD) or "negative". We also statistically 255 compared mean values reported in Table 2 to Table 1 256 in order to exclude a selection bias due to the unavail-257 able samples in the plasma analysis. There were no 258 differences between the "positive" (prodromal AD) 259 and "negative" aMCI groups (data not shown). T12 and T18 (p < 0.001). This difference was com-296 mon to the "negative" and "positive" aMCI groups.
297
To refine the above statistical analysis, we applied
298
Linear Mixed Models to the plasma measures using 299 the factors Group ("positive" and "negative" aMCI)
300
and Time (T0, T12, and T18). Table 3 Linear Mixed Models for the analysis of selected plasma molecules in aMCI patients stratified as "positive", as prodromal AD, and "negative" as a control group, according to cut-offs of CSF A␤ 42 /P-tau [22] 
